Premium
Sequential therapy in renal cell carcinoma
Author(s) -
Escudier Bernard,
Goupil Marine Gross,
Massard Christophe,
Fizazi Karim
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24241
Subject(s) - medicine , sunitinib , temsirolimus , sorafenib , renal cell carcinoma , bevacizumab , oncology , cancer , overall survival , carcinoma , kidney cancer , surgery , chemotherapy , discovery and development of mtor inhibitors , hepatocellular carcinoma , pi3k/akt/mtor pathway , apoptosis , biochemistry , chemistry
Abstract Because of the recent approval of several drugs for the treatment of renal cell carcinoma (including sorafenib, sunitinib, temsirolimus, and, in Europe, bevacizumab plus interferon), the use of sequential therapy has become routine practice. There is now evidence that administering these targeted agents sequentially provides clinical benefit by inducing tumor shrinkage and prolonged progression‐free survival (PFS) in a large number of patients. However, data regarding overall survival (OS) are still pending. By adding these drugs in an adequate order, one can expect an increase in overall PFS of up to 27 months and a subsequent improvement in the OS of patients with renal cell carcinoma. It has been recently reported that the OS of patients treated with sunitinib in the first‐line setting was 26 months. Expecting a survival of 40 months does appear possible based on currently available data, although this assumption will have to be proven in the future. Cancer 2009;115(10 suppl):2321‐6. © 2009 American Cancer Society.